MS Treatments Market to Grow $6 Billion by 2011 as the Numbers of Both New Patients and New Treatment Formulas Rise

July 27, 2007 (PRLEAP.COM) Health News
New York, July 27, 2007— Steady, double-digit growth pushed the worldwide sales of multiple sclerosis (MS) treatments from $4.4 billion in 2004 to nearly $5.9 billion in 2006, a trend Multiple Sclerosis: Worldwide Market Outlook to 2011, a new report by Kalorama Information, expects to continue through 2011, when the market should reach $11.9 billion.

Approval of four MS treatment therapies, which generated more than $1 billion in sales each in 2006, contributed to the market’s 15% increase over 2004, and Kalorama Information expects that new formulations for existing treatments and new developments, as well as the rising rate of MS across several regions of the world, will support a 15.2% revenue increase over the next five years.

Multiple sclerosis, a chronic demyelinating disease and autoimmune disorder that causes significant disability, inflammation, and scarring of the myelin sheaths covering nerves, first appears in individuals between ages 10 and 50. MS is two to three times more common in women than men, and it occurs at a higher rate among individuals from white northern latitudes. An estimated 2.5 million people worldwide suffer from this condition: in Canada, approximately three people are diagnosed every day.

“The focus of multiple sclerosis treatment has been within North American and Northern European countries that have displayed prevalence of more than 100 per 100,000 populations,” said Steven Heffner, Executive Publisher of Kalorama Information. “However, this disease is undergoing dramatic changes. Regions that were once considered to have low incidence and prevalence of multiple sclerosis are now displaying increases that were not apparent even within the last 10 years.”

Multiple Sclerosis focuses on currently marketed products in the MS market and includes statistical information for MS worldwide and by selected countries, with special emphasis on the major pharmaceutical markets: the United States, Europe, and Japan. The report also analyzes new treatments in the pipeline, triggers and risk factors, leading competitors, and current issues and trends affecting the industry. This report can be purchased directly from Kalorama Information by visiting It is also available at

About Kalorama Information
Kalorama Information supplies the latest in independent market research on worldwide medical markets. For more information, contact Tom Ehart at 240-747-3014 or, or visit